AR076705A1 - Agentes inductores de la apoptosis para el tratamiento del cancer y enfermedades inmunes y autoinmunes - Google Patents

Agentes inductores de la apoptosis para el tratamiento del cancer y enfermedades inmunes y autoinmunes

Info

Publication number
AR076705A1
AR076705A1 ARP100101806A ARP100101806A AR076705A1 AR 076705 A1 AR076705 A1 AR 076705A1 AR P100101806 A ARP100101806 A AR P100101806A AR P100101806 A ARP100101806 A AR P100101806A AR 076705 A1 AR076705 A1 AR 076705A1
Authority
AR
Argentina
Prior art keywords
nhc
nhr1
nr1c
fused
so2n
Prior art date
Application number
ARP100101806A
Other languages
English (en)
Inventor
Steven Elmore
Xiaohong Song
Andrew Souers
Gerard M Sullivan
Gary Wang
Milan Bruncko
Hong Ding
Michael Wendt
Le Wang
Lisa A Hasvold
Robert A Mantei
George A Doherty
Laura Hexamer
Zhi-Fu Tao
Xilu Wang
Todd M Hansen
Aaron Kunzer
Original Assignee
Abbott Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42677657&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR076705(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Abbott Lab filed Critical Abbott Lab
Publication of AR076705A1 publication Critical patent/AR076705A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Abstract

Compuestos que inhiben la actividad de proteínas anti-apoptoticas Bc1-2, composiciones que contienen a dichos compuestos y métodos de tratamiento de enfermedades durante cuyo transcurso hay expresion de la proteína anti-apoptotica Bc1-2. Reivindicacion 1: Un compuesto caracterizado porque tiene la Formula (1), o una sal terapéuticamente aceptable del mismo, en donde A1 es N o C(A2); A2 es H, R1, OR1, SR1, S(O)R1, SO2R1, C(O)R1, C(O)OR1, OC(O)R1, NHR1, N(R1)2, C(O)NHR1, C(O)N(R1)2, NHC(O)R1, NR1C(O)R1, NHC(O)OR1, NR1C(O)OR1, NHC(O)NH2, NHC(O)NHR1, NHC(O)N(R1)2, NR1C(O)NHR1, NR1C(O)N(R1)2, SO2NH2, SO2NHR1, SO2N(R1)2, NHSO2R1, NR1SO2R1, NHSO2NHR1, NHSO2N(R1)2, NR1SO2NHR1, NR1SO2N(R1)2, C(O)NHNOH, C(O)NHNOR1, C(O)NHSO2R1, C(NH)NH2, C(NH)NHR1, C(NH)N(R1)2 NHSO2NHR1, NHSO2N(CH3)R1, N(CH3)SO2N(CH3)R1, F, Cl, Br, I, CN, NO2, N3, OH, C(O)H, CHNOH, CH(NOCH3), CF3, C(O)OH, C(O)NH2 o C(O)OR1A; B1 es H, R1, OR1, SR1, S(O)R1, SO2R1, C(O)R1, C(O)OR1, OC(O)R1, NHR1, N(R1)2, C(O)NHR1, C(O)N(R1)2, NHC(O)R1, NR1C(O)R1, NHC(O)OR1, NR1C(O)OR1, NHC(O)NH2, NHC(O)NHR1, NHC(O)N(R1)2, NR1C(O)NHR1, NR1C(O)N(R1)2, SO2NH2, SO2NHR1, SO2N(R1)2, NHSO2R1, NR1SO2R1, NHSO2NHR1, NHSO2N(R1)2, NR1SO2NHR1, NR1SO2N(R1)2, C(O)NHNOH, C(O)NHNOR1, C(O)NHSO2R1, C(NH)NH2, C(NH)NHR1, C(NH)N(R1)2 NHSO2NHR1, NHSO2N(CH3)R1, N(CH3)SO2N(CH3)R1, F, CI, Br, I, CN, NO2, N3, OH, C(O)H, CHNOH, CH(NOCH3), CF3, C(O)OH, C(O)NH2 o C(O)OR1A; D1 es H, R1, OR1, SR1, S(O)R1, SO2R1, C(O)R1, C(O)OR1, OC(O)R1, NHR1, N(R1)2, C(O)NHR1, C(O)N(R1)2, NHC(O)R1, NR1C(O)R1, NHC(O)OR1, NR1C(O)OR1, NHC(O)NH2, NHC(O)NHR1, NHC(O)N(R1)2, NR1C(O)NHR1, NR1C(O)N(R1)2, SO2NH2, SO2NHR1, SO2N(R1)2, NHSO2R1, NR1SO2R1, NHSO2NHR1, NHSO2N(R1)2; NR1SO2NHR1, NR1SO2N(R1)2, C(O)NHNOH, C(O)NHNOR1, C(O)NHSO2R1, C(NH)NH2, C(NH)NHR1, C(NH)N(R1)2 NHSO2NHR1, NHSO2N(CH3)R1, N(CH3)SO2N(CH3)R1, F, CI, Br, I, CN, NO2, N3, OH, C(O)H, CHNOH, CH(NOCH3), CF3, C(O)OH, C(O)NH2 o C(O)OR1A; E1 es H, R1, OR1, SR1, S(O)R1, SO2R1, C(O)R1, C(O)OR1, OC(O)R1, NHR1, N(R1)2, C(O)NHR1, C(O)N(R1)2, NHC(O)R1, NR1C(O)R1, NHC(O)OR1, NR1C(O)OR1, NHC(O)NH2, NHC(O)NHR1, NHC(O)N(R1)2, NR1C(O)NHR1, NR1C(O)N(R1)2, SO2NH2, SO2NHR1, SO2N(R1)2, NHSO2R1, NR1SO2R1, NHSO2NHR1, NHSO2N(R1)2, NR1SO2NHR1, NR1SO2N(R1)2, C(O)NHNOH, C(O)NHNOR1, C(O)NHSO2R1, C(NH))NH2, C(NH)NHR1, C(NH)N(R1)2 NHSO2NHR1, NHSO2N(CH3)R1, N(CH3)SO2N(CH3)R1, F, Cl, Br, I, CN, NO2, N3, OH, C(O)H, CHNOH, CH(NOCH3), CF3, C(O)OH, C(O)NH2 o C(O)OR1A; y Y1 es H, CN, NO2, C(O)OH, F, CI, Br, I, CF3, OCF3, CF2CF3, OCF2CF3, R17, OR17, C(O)R17, C(O)OR17, SR17, SO2R17, NH2, NHR17, N(R17)2, NHC(O)R17, C(O)NH2, C(O)NHR17, C(O)N(R17)2, NHS(O)R17 o NHSO2R17; o E1 y Y1, junto con los átomos a los cuales están unidos, son benceno, naftileno, heteroareno cicloalcano, cicloalqueno, heterocicloalcano o heterocicloalqueno; y A2, B1, y D1 se seleccionan en forma independiente entre H, R1, OR1, SR1, S(O)R1, SO2R1, C(O)R1, C(O)OR1, OC(O)R1, NHR1, N(R1)2, C(O)NHR1, C(O)N(R1)2, NHC(O)R1, NR1C(O)R1, NHC(O)OR1, NR1C(O)OR1, NHC(O)NH2, NHC(O)NHR1, NHC(O)N(R1)2, NR1C(O)NHR1, NR1C(O)N(R1)2, SO2NH2, SO2NHR1, SO2N(R1)2, NHSO2R1, NR1SO2R1, NHSO2NHR1, NHSO2N(R1)2, NR1SO2NHR1, NR1SO2N(R1)2, C(O)NHNOH, C(O)NHNOR1, C(O)NHSO2R1, C(NH)NH2, C(NH)NHR1, C(NH)N(R1)2 NHSO2NHR1, NHSO2N(CH3)R1, N(CH3)SO2N(CH3)R1, F, CL, Br, I, CN, NO2 N3, OH, C(O)H, CHNOH, CH(NOCH3), CF3, C(O)OH, C(O)NH2 o C(O)OR1A; o Y1 y B1, junto con los átomos a los cuales están unidos, son benceno, naftileno, heteroareno, cicloalcano, cicloalqueno, heterocicloalcano o heterocicloalqueno; y A2, D1, y E1 se seleccionan en forma independiente entre H, R1, OR1, SR1, S(O)R1, SO2R1, C(O)R1, C(O)OR1, OC(O)R1, NHR1, N(R1)2, C(O)NHR1, C(O)N(R1)2, NHC(O)R1, NR1C(O)R1, NHC(O)OR1, NR1C(O)OR1, NHC(O)NH2, NHC(O)NHR1, NHC(O)N(R1)2, NR1C(O)NHR1, NR1C(O)N(R1)2, SO2NH2, SO2NHR1, SO2N(R1)2, NHSO2R1, NR1SO2R1, NHSO2NHR1, NHSO2N(R1)2, NR1SO2NHR1, NR1SO2N(R1)2, C(O)NHNOH, C(O)NHNOR1, C(O)NHSO2R1, C(NH)NH2, C(NH)NHR1, C(NH)N(R1)2 NHSO2NHR1, NHSO2N(CH3)R1, N(CH3)SO2N(CH3)R1, F, Cl, Br, I, CN, NO2, N3, OH, C(O)H, CHNOH, CH(NOCH3), CF3, C(O)OH, C(O)NH2 o C(O)OR1A; o A2 y B1, junto con los átomos a los cuales están unidos, son benceno, naftileno, heteroareno cicloalcano, cicloalqueno, heterocicloalcano o heterocicloalqueno; y D1, E1, y Y1 se seleccionan en forma independiente entre H, R1, OR1, S(O)R1, SO2R1, C(O)R1, C(O)OR1, OC(O)R1, NHR1, N(R1)2, C(O)NHR1, C(O)N(R1)2, NHC(O)R1, NR1C(O)R1, NHC(O)OR1, NR1C(O)OR1, NHC(O)NH2, NHC(O)NHR1, NHC(O)N(R1)2, NR1C(O)NHR1, NR1C(O)N(R1)2, SO2NH2, SO2NHR1, SO2N(R1)2, NHSO2R1, NR1SO2R1, NHSO2NHR1, NHSO2N(R1)2, NR1SO2NHR1, NR1SO2N(R1)2, C(O)NHNOH, C(O)NHNOR1, C(O)NHSO2R1, C(NH)NH2, C(NH)NHR1, C(NH)N(R1)2 NHSO2NHR1, NHSO2N(CH3)R1, N(CH3)SO2N(CH3)R1, F, CI, Br, I, CN, NO2, N3, OH, C(O)H, CHNOH, CH(NOCH3), CF3, C(O)OH, C(O)NH2 o C(O)OR1A; o A2 y D1, junto con los átomos a los cuales están unidos, son benceno, naftaleno, heteroareno, cicloalcano, cicloalqueno, heterocicloalcano o heterocicloalqueno; y B1, E1, y Y1 se seleccionan en forma independiente entre H, R1, OR1, SR1, S(O)R1, SO2R1, C(O)R1, C(O)OR1, OC(O)R1, NHR1, N(R1)2, C(O)NHR1, C(O)N(R1)2, NHC(O)R1, NR1C(O)R1, NHC(O)OR1, NR1C(O)OR1, NHC(O)NH2, NHC(O)NHR1, NHC(O)N(R1)2, NR1C(O)NHR1, NR1C(O)N(R1)2, SO2NH2, SO2NHR1, SO2N(R1)2, NHSO2R1, NR1SO2R1, NHSO2NHR1, NHSO2N(R1)2, NR1SO2NHR1, NR1SO2N(R1)2, C(O)NHNOH, C(O)NHNOR1, C(O)NHSO2R1, C(NH)NH2, C(NH)NHR1, C(NH)N(R1)2 NHSO2NHR1, NHSO2N(CH3)R1, N(CH3)SO2N(CH3)R1, F, CI, Br, I, CN, NO2 N3, OH, C(O)H, CHNOH, CH(NOCH3), CF3, C(O)OH, C(O)NH2 o C(O)OR1A; G1 es H, o C(O)O; R es alquilo; R1 es R2, R3, R4 o R5; R1A es cicloalquilo, cicloalquenilo o cicloalquinilo; R2 es fenilo, que no está fusionado o está fusionado con R2A; R2A es benceno, heteroareno, cicloalcano, cicloalqueno, heterocicloalcano o heterocicloalqueno; R3 es heteroarilo, que no está fusionado o está fusionado con R3A; R3A es benceno, heteroareno, cicloalcano, cicloalqueno, heterocicloalcano o heterocicloalqueno; R4 es cicloalquilo, cicloalquenilo, heterocicloalquilo o heterocicloalquenilo, cada uno de cuales no está fusionado o está fusionado con R4A; R4A es benceno, heteroareno, cicloalcano, cicloalqueno, heterocicloalcano o heterocicloalqueno; R5 es alquilo, alquenilo o alquinilo, cada uno de los cuales no esta sustituido o está sustituido con uno o dos o tres sustituyentes seleccionados en forma independiente entre R6, NC(R6A)(R6B), R7, OR7, SR7, S(O)R7, SO2R7, NHR7, N(R7)2, C(O)R7, C(O)NH2, C(O)NHR7, C(O)N(R7)2, NHC(O)R7, NR7C(O)R7, NHSO2R7, NHC(O)OR7, SO2NH2, SO2NHR7, SO2N(R7)2, NHC(O)NH2, NHC(O)NHR7, NHC(O)CH(CH3)NHC(O)CH(CH3)NH2, NHC(O)CH(CH3)NHC(O)CH(CH3)NHR7, OH, (O), C(O)OH, N3, CN, NH2, CF3, CF2CF3, F, CI, Br o I; R6 es C2-5- eespiroalquilo, cada uno de los cuales no esta sustituido o está sustituido con OH, (O), N3, CN, CF3, CF2CF3, F, Cl, Br, I, NH2, NH(CH3) o N(CH3)2; R6A y R6B se seleccionan en forma independiente entre alquilo o, junto con el N al cual estan unidos, R6C; R6C es aziridin-1-ilo, azetidin-1-ilo, pirrolidin-1-ilo o piperidin-1-ilo, donde cada uno tiene una unidad CH2 no reemplazada o reemplazada con O, C(O), CNOH, CNOCH3, S, S(O), SO2 o NH; R7 es R8, R9, R10 o R11; R8 es fenilo, que no está fusionado o está fusionado con R8A; R8A es benceno, heteroareno, cicloalcano, cicloalqueno, heterocicloalcano o heterocicloalqueno; R9 es heteroarilo, que no está fusionado o está fusionado con R9A; R9A es benceno, heteroareno, cicloalcano, cicloalqueno, heterocicloalcano o heterocicloalqueno; R10 es cicloalquilo, cicloalquenilo, heterocicloalquilo o heterocicloalquenilo, cada uno de los cuales no está fusionado o está fusionado con R10N; R10A es benceno, heteroareno, cicloalcano, cicloalqueno, heterocicloalcano o heterocicloalqueno; R11 es alquilo, alquenilo o alquinilo, cada uno de los cuales no esta sustituido o está sustituido con uno o dos o tres sustituyentes seleccionados en forma independiente entre R12, OR12, SR12, S(O)R12, SO2R12, C(O)R12, CO(O)R12, OC(O)R12, OC(O)OR12, NH2, NHR12, N(R12)2, NHC(O)R12, NR12C(O)R12, NHS(O)2R12, NR12S(O)2R12, NHC(O)OR12, NR12C(O)OR12, NHC(O)NH2, NHC(O)NHR12, NHC(O)N(R12)2, NR12C(O)NHR12, NR12C(O)N(R12)2, C(O)NH2, C(O)NHR12, C(O)N(R12)2, C(O)NHOH, C(O)NHOR12, C(O)NHSO2R12, C(O)NR12SO2R12, SO2NH2, SO2NHR12, SO2N(R12)2, C(O)H, C(O)OH, C(N)NH2, C(N)NHR12, C(N)N(R12)2, CNOH, CNOCH3, OH, (O), CN, N3, NO2, CF3, CF2CF3, OCF3, OCF2CF3, F, CI, Br o I; R12 es R13, R14, R15 o R16; R13 es fenilo, que no está fusionado o está fusionado con R13A; R13A es benceno, heteroareno, cicloalcano, cicloalqueno, heterocicloalcano o heterocicloalqueno; R14 es heteroarilo, que no está fusionado o está fusionado con R14A; R14A es benceno, heteroareno, cicloalcano, cicloalqueno, heterocicloalcano o heterocicloalqueno; R15 es cicloalcano, cicloalqueno, heterocicloalcano o heterocicloalqueno, cada uno de los cuales no está fusionado o está fusionado con R15A; R15A es benceno, heteroareno, cicloalcano, cicloaIqueno, heterocicloalcano o heterocicloalqueno; R16 es alquilo, alquenilo o alquinilo; R17 es R18, R19, R20 o R21; R18 es fenilo, que no está fusionado o está fusionado con R18A; R18A es benceno, heteroareno, cicloalcano, cicloalqueno, heterocicloalcano o heterocicloalqueno; R19 es heteroarilo, que no está fusionado o está fusionado con R19A; R19A es benceno, heteroareno, cicloalcano, cicloalqueno, heterocicloalcano o heterocicloalqueno; R20 es cicloalquilo, cicloalquenilo, heterocicloalquilo o heterocicloalquenilo cada uno de los cuales no está fusionado o está fusionado con R20A; R20A es benceno, heteroareno, cicloalcano, cicloalqueno, heterocicloalcano o heterocicloalqueno; R21 es alquilo, alquenilo o alquinilo, cada uno de los cuales no esta sustituido o está sustituido con uno o dos o tres sustituyentes seleccionados en forma independiente entre R22, OR22, SR22, S(O)R22, SO2R22, C(O)R22, CO(O)R22, OC(O)R22, OC(O)OR22, NH2, NHR22, N(R22)2, NHC(O)R22, NR22C(O)R22, NHS(O)2R22, NR22S(O)2R22, NHC(O)OR22, NR22C(O)OR22, NHC(O)NH2, NHC(O)NHR22, NHC(O)N(R22)2, NR22
ARP100101806A 2009-05-26 2010-05-26 Agentes inductores de la apoptosis para el tratamiento del cancer y enfermedades inmunes y autoinmunes AR076705A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US18120309P 2009-05-26 2009-05-26

Publications (1)

Publication Number Publication Date
AR076705A1 true AR076705A1 (es) 2011-06-29

Family

ID=42677657

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP100101806A AR076705A1 (es) 2009-05-26 2010-05-26 Agentes inductores de la apoptosis para el tratamiento del cancer y enfermedades inmunes y autoinmunes
ARP170102895A AR109974A2 (es) 2009-05-26 2017-10-18 Agentes inductores de apoptosis para el tratamiento de cáncer y enfermedades inmunes y autoinmunes

Family Applications After (1)

Application Number Title Priority Date Filing Date
ARP170102895A AR109974A2 (es) 2009-05-26 2017-10-18 Agentes inductores de apoptosis para el tratamiento de cáncer y enfermedades inmunes y autoinmunes

Country Status (43)

Country Link
US (1) US8580794B2 (es)
EP (3) EP2944638A1 (es)
JP (7) JP5747025B2 (es)
KR (8) KR20170037683A (es)
CN (5) CN102448959B (es)
AR (2) AR076705A1 (es)
AU (1) AU2010254160C1 (es)
BR (2) BRPI1014359B1 (es)
CA (4) CA2759182C (es)
CL (1) CL2011002949A1 (es)
CO (1) CO6480950A2 (es)
CR (2) CR20170019A (es)
CY (2) CY1117423T1 (es)
DK (1) DK2435432T6 (es)
DO (1) DOP2011000367A (es)
EC (1) ECSP11011554A (es)
ES (1) ES2546294T3 (es)
FI (1) FI2435432T6 (es)
HK (2) HK1163099A1 (es)
HR (1) HRP20151001T4 (es)
HU (2) HUE027698T2 (es)
IL (5) IL299019A (es)
LT (1) LTC2435432I2 (es)
ME (1) ME02205B (es)
MX (2) MX339469B (es)
MY (1) MY155645A (es)
NL (1) NL300873I2 (es)
NO (1) NO2017023I2 (es)
NZ (1) NZ595708A (es)
PE (1) PE20120345A1 (es)
PH (1) PH12015500297A1 (es)
PL (1) PL2435432T6 (es)
PT (1) PT2435432E (es)
RS (1) RS54234B2 (es)
RU (3) RU2535347C3 (es)
SG (2) SG175253A1 (es)
SI (1) SI2435432T1 (es)
SM (1) SMT201500225B (es)
TW (3) TWI537269B (es)
UA (1) UA106079C2 (es)
UY (3) UY32668A (es)
WO (1) WO2010138588A2 (es)
ZA (1) ZA201108616B (es)

Families Citing this family (108)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100160322A1 (en) 2008-12-04 2010-06-24 Abbott Laboratories Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
US8557983B2 (en) 2008-12-04 2013-10-15 Abbvie Inc. Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
SG10201500767RA (en) 2008-12-05 2015-04-29 Abbvie Inc Sulfonamide derivatives as bcl-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases
US8586754B2 (en) 2008-12-05 2013-11-19 Abbvie Inc. BCL-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases
US8563735B2 (en) 2008-12-05 2013-10-22 Abbvie Inc. Bcl-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases
SG193849A1 (en) * 2009-01-19 2013-10-30 Abbott Lab Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
US20220315555A1 (en) 2009-05-26 2022-10-06 Abbvie Inc. Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases
KR20170037683A (ko) * 2009-05-26 2017-04-04 애브비 아일랜드 언리미티드 컴퍼니 암，면역 질환 및 자가면역 질환의 치료를 위한 아폽토시스-유도제
US9034875B2 (en) 2009-05-26 2015-05-19 Abbvie Inc. Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
US8546399B2 (en) 2009-05-26 2013-10-01 Abbvie Inc. Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases
TWI520960B (zh) 2010-05-26 2016-02-11 艾伯維有限公司 用於治療癌症及免疫及自體免疫疾病之細胞凋亡誘導劑
CA3007787C (en) 2010-06-03 2020-03-10 Pharmacyclics Llc The use of inhibitors of bruton's tyrosine kinase (btk)
TWI535712B (zh) 2010-08-06 2016-06-01 阿斯特捷利康公司 化合物
UA113500C2 (xx) * 2010-10-29 2017-02-10 Одержані екструзією розплаву тверді дисперсії, що містять індукуючий апоптоз засіб
CA2811805A1 (en) * 2010-10-29 2012-05-03 Abbvie Inc. Solid dispersions containing an apoptosis-inducing agent
CN107266435A (zh) 2010-11-23 2017-10-20 Abbvie 公司 细胞凋亡诱导剂的盐和晶形
RU2593231C2 (ru) * 2010-11-23 2016-08-10 ЭббВи Айэленд Анлимитед Компани Способы лечения с использованием селективных ингибиторов bcl-2
US9108910B2 (en) 2011-02-15 2015-08-18 Ube Industries, Ltd. Industrial methods for producing arylsulfur pentafluorides
CN102241649A (zh) * 2011-07-08 2011-11-16 陈飞 3-四氢呋喃甲醇的制备方法
CN103958508B (zh) 2011-10-14 2019-02-12 艾伯维公司 用于治疗癌症以及免疫与自身免疫性疾病的细胞凋亡诱导剂
WO2013185202A1 (en) * 2012-06-14 2013-12-19 Beta Pharma Canada Inc Apoptosis inducers
WO2014018567A1 (en) 2012-07-24 2014-01-30 Pharmacyclics, Inc. Mutations associated with resistance to inhibitors of bruton's tyrosine kinase (btk)
CN104736153B (zh) * 2012-08-13 2018-06-29 艾伯维公司 细胞凋亡诱导剂
KR20200110711A (ko) 2012-09-07 2020-09-24 제넨테크, 인크. Ｉｉ형 항-ｃｄ20 항체와 선택적 ｂｃｌ-2 억제제와의 병용 치료요법
LT6064B (lt) 2012-10-15 2014-08-25 Vilniaus Universitetas Fluorinti benzensulfonamidai kaip karboanhidrazės inhibitoriai
US20150283142A1 (en) * 2013-03-15 2015-10-08 Infinity Pharmaceuticals, Inc. Treatment of cancers using pi3 kinase isoform modulators
PT2914296T (pt) * 2012-11-01 2018-10-30 Infinity Pharmaceuticals Inc Tratamento de cancros utilizando moduladores de isoformas de pi3-quinase
US9006438B2 (en) 2013-03-13 2015-04-14 Abbvie Inc. Processes for the preparation of an apoptosis-inducing agent
US20140275082A1 (en) * 2013-03-14 2014-09-18 Abbvie Inc. Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
MX369503B (es) * 2013-04-08 2019-11-11 Pharmacyclics Llc Combinaciones que comprenden ibrutinib y abt-199 para tratar trastornos proliferativos de células b y métodos de uso de las mismas.
TWI594975B (zh) 2013-04-24 2017-08-11 第一三共股份有限公司 二羧酸化合物
US9238652B2 (en) 2014-03-04 2016-01-19 Abbvie Inc. Processes for the preparation of an apoptosis-inducing agent
US11331328B2 (en) 2014-05-05 2022-05-17 Bioventures, Llc Compositions and methods for inhibiting antiapoptotic Bcl-2 proteins as anti-aging agents
EP3177144A4 (en) 2014-07-22 2018-01-24 Bioventures, LLC. Compositions and methods for selectively depleting senescent cells
CN104163798A (zh) * 2014-07-29 2014-11-26 苏州康润医药有限公司 3-氨基-8-三氟甲基喹啉的合成方法
HRP20211813T1 (hr) 2014-08-11 2022-03-04 Acerta Pharma B.V. Terapeutske kombinacije inhibitora btk i inhibitora bcl-2
RU2020134082A (ru) 2014-10-06 2020-11-27 Вертекс Фармасьютикалз Инкорпорейтед Модуляторы регулятора трансмембранной проводимости при муковисцидозе
US10195213B2 (en) 2015-03-13 2019-02-05 Unity Biotechnology, Inc. Chemical entities that kill senescent cells for use in treating age-related disease
ES2731377T3 (es) 2015-07-07 2019-11-15 Hoffmann La Roche Politerapia con un conjugado anticuerpo anti-HER2-fármaco y un inhibidor de bcl-2
WO2017063572A1 (zh) * 2015-10-13 2017-04-20 苏州晶云药物科技有限公司 细胞凋亡诱导剂的新晶型及其制备方法
WO2017096303A2 (en) 2015-12-04 2017-06-08 Portola Pharmaceuticals, Inc. Cerdulatinib for treating hematological cancers
WO2017156398A1 (en) 2016-03-10 2017-09-14 Assia Chemical Industries Ltd. Solid state forms of venetoclax and processes for preparation of venetoclax
WO2017160954A1 (en) 2016-03-15 2017-09-21 Seattle Genetics, Inc. Combinations of pbd-based antibody drug conjugates with bcl-2 inhibitors
SG11201807965YA (en) 2016-03-15 2018-10-30 Oryzon Genomics Sa Combinations of lsd1 inhibitors for use in the treatment of solid tumors
WO2017157813A1 (en) 2016-03-15 2017-09-21 F. Hoffmann-La Roche Ag Combinations of lsd1 inhibitors for the treatment of hematological malignancies
PL3436446T3 (pl) 2016-03-31 2023-09-11 Vertex Pharmaceuticals Incorporated Modulatory mukowiscydozowego przezbłonowego regulatora przewodnictwa
JP6936498B2 (ja) 2016-04-21 2021-09-15 バイオベンチャーズ・リミテッド・ライアビリティ・カンパニーＢｉｏＶｅｎｔｕｒｅｓ， ＬＬＣ 抗アポトーシス性Ｂｃｌ−２ファミリータンパク質の分解を誘導する化合物及びその使用
CN109311871B (zh) 2016-08-05 2020-02-28 密歇根大学董事会 作为bcl-2抑制剂的n-(苯基磺酰基)苯甲酰胺及相关化合物
WO2018041248A1 (zh) * 2016-09-01 2018-03-08 北京赛林泰医药技术有限公司 Bcl-2选择性抑制剂及其制备和用途
NZ752486A (en) 2016-09-30 2023-04-28 Vertex Pharma Modulator of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator
CN106749233B (zh) * 2016-11-24 2020-04-21 中山大学 一类磺酰胺衍生物及其应用
BR112019011626A2 (pt) 2016-12-09 2019-10-22 Vertex Pharma modulador de regulador de condutância transmembrana na fibrose cística, composições farmacêuticas, métodos de tratamento e processo para a produção do modulador
US11053239B2 (en) 2017-01-07 2021-07-06 Fochon Pharmaceuticals, Ltd. Compounds as BLC-2-selective apoptosis-inducing agents
JOP20190191A1 (ar) 2017-02-22 2019-08-08 Astrazeneca Ab وحدات شجرية علاجية
WO2018167652A1 (en) * 2017-03-13 2018-09-20 Laurus Labs Limited Process for preparation of amorphous form of venetoclax
SI3612531T1 (sl) * 2017-04-18 2022-11-30 Shanghai Fochon Pharmaceutical Co., Ltd. Sredstva, ki sprožajo apoptozo
CN107089981A (zh) * 2017-04-24 2017-08-25 杭州科耀医药科技有限公司 一种BCL‑2抑制剂Venetoclax的合成方法
BR112019025801A2 (pt) 2017-06-08 2020-07-07 Vertex Pharmaceuticals Incorporated métodos de tratamento para fibrose cística
EP3626241A4 (en) * 2017-06-26 2020-05-27 Shenzhen Targetrx, Inc. N-BENZOLSULFONYLBENZAMIDE COMPOUND FOR INHIBITING BCL-2 PROTEIN AND COMPOSITION AND USE THEREOF
WO2019018395A1 (en) 2017-07-17 2019-01-24 Vertex Pharmaceuticals Incorporated METHODS OF TREATING CYSTIC FIBROSIS
WO2019020610A1 (en) 2017-07-26 2019-01-31 F. Hoffmann-La Roche Ag POLYTHERAPY USING BET INHIBITOR AND BCL-2 INHIBITOR
EP3658584A1 (en) 2017-07-26 2020-06-03 H. Hoffnabb-La Roche Ag Combination therapy with a bet inhibitor, a bcl-2 inhibitor and an anti-cd20 antibody
MA49752A (fr) 2017-08-02 2021-04-21 Vertex Pharma Procédés de préparation de composés de pyrrolidine
KR20200092308A (ko) 2017-08-23 2020-08-03 뉴에이브 파마슈티칼 인크. Bcl-2 억제제
EP3697774A1 (en) 2017-10-19 2020-08-26 Vertex Pharmaceuticals Incorporated Crystalline forms and compositions of cftr modulators
CN108037196B (zh) * 2017-11-23 2020-06-23 中山奕安泰医药科技有限公司 一种3-硝基-4-[[(四氢-2h-吡喃-4-基)甲基]氨基]苯磺酰胺的检测方法
WO2019113476A2 (en) 2017-12-08 2019-06-13 Vertex Pharmaceuticals Incorporated Processes for making modulators of cystic fibrosis transmembrane conductance regulator
EP3737681A4 (en) 2018-01-10 2022-01-12 Recurium IP Holdings, LLC BENZAMIDE COMPOUNDS
EP3743069A4 (en) 2018-01-22 2021-06-09 BioVentures, LLC DEGRADER OF BCL-2 PROTEIN FOR CANCER TREATMENT
TWI810243B (zh) 2018-02-05 2023-08-01 美商維泰克斯製藥公司 用於治療囊腫纖化症之醫藥組合物
AU2019221672A1 (en) 2018-02-16 2020-09-03 Abbvie Inc. Selective BCL-2 inhibitors in combination with an anti-PD- 1 or an anti-PD-L1 antibody for the treatment of cancers
WO2019178433A1 (en) 2018-03-15 2019-09-19 Abbvie Inc. Abbv-621 in combination with anti-cancer agents for the treatment of pancreatic cancer
CN114369094B (zh) * 2018-03-30 2023-09-29 正大天晴药业集团股份有限公司 三氟甲基取代的磺酰胺类选择性bcl-2抑制剂
EP3774825A1 (en) 2018-04-13 2021-02-17 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator
US11420968B2 (en) * 2018-04-29 2022-08-23 Beigene, Ltd. Bcl-2 inhibitors
WO2019213606A2 (en) 2018-05-04 2019-11-07 Portola Pharmaceuticals, Inc. Solid forms of cerdulatinib
WO2020023435A1 (en) 2018-07-24 2020-01-30 Albany Molecular Research, Inc. Venetoclax basic salts and processes for the purification of venetoclax
TW202023568A (zh) 2018-07-30 2020-07-01 瑞典商阿斯特捷利康公司 用於治療癌症之組合療法
US11478469B2 (en) 2018-07-31 2022-10-25 Ascentage Pharma (Suzhou) Co., Ltd. Combination product of BCL-2 inhibitor and MDM2 inhibitor and use thereof in the prevention and/or treatment of diseases
US11491167B2 (en) 2018-07-31 2022-11-08 Ascentage Pharma (Suzhou) Co., Ltd. Combination product of Bcl-2 inhibitor and chemotherapeutic agent and use thereof in the prevention and/or treatment of diseases
CN114522167A (zh) 2018-07-31 2022-05-24 苏州亚盛药业有限公司 Bcl-2抑制剂或Bcl-2/Bcl-xL抑制剂与BTK抑制剂的组合产品及其用途
JP2021516262A (ja) 2018-07-31 2021-07-01 アセンテージ ファーマ（スーチョウ）カンパニー，リミティド リツキシマブ及び／若しくはベンダムスチンと組み合わされたＢｃｌ−２阻害剤又はＣＨＯＰと組み合わされたＢｃｌ−２阻害剤の相乗的な抗腫瘍効果
US11903950B2 (en) 2018-08-22 2024-02-20 Newave Pharmaceutical Inc. BCL-2 inhibitors
US20220002290A1 (en) 2018-10-29 2022-01-06 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Trifluoromethyl-substituted sulfonamide as bcl-2-selective inhibitor
CN109320516A (zh) * 2018-11-30 2019-02-12 重庆三圣实业股份有限公司 一种维奈妥拉中间体的制备方法及其产品
CN109438441A (zh) * 2018-11-30 2019-03-08 重庆三圣实业股份有限公司 一种维奈妥拉的制备方法及其产品
WO2020232214A1 (en) 2019-05-14 2020-11-19 Abbvie Inc. Treating acute myeloid leukemia (aml) with mivebresib, a bromodomain inhibitor
WO2020234445A1 (en) 2019-05-23 2020-11-26 F. Hoffmann-La Roche Ag Combination therapy with a bet inhibitor and a bcl-2 inhibitor
JP2022533740A (ja) 2019-05-24 2022-07-25 チア タイ ティエンチン ファーマシューティカル グループ カンパニー リミテッド メチル基及びトリフルオロメチル基を含む二置換スルファミド系選択的ｂｃｌ－２阻害剤
WO2021037933A1 (en) 2019-08-28 2021-03-04 Astrazeneca Ab Combination of azd2811 nanoparticles, 5-azacitidine and venetoclax for use in the treatment of cancer
CN112661751A (zh) * 2019-10-16 2021-04-16 南京天印健华医药科技有限公司 作为bcl-2抑制剂的杂环化合物
CN114929689A (zh) * 2019-10-28 2022-08-19 百济神州有限公司 Bcl-2抑制剂
WO2021110102A1 (en) * 2019-12-02 2021-06-10 Beigene, Ltd. Methods of cancer treatment using bcl-2 inhibitor
US20230174528A1 (en) 2020-04-29 2023-06-08 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Crystal of trifluoromethyl/chloro disubstituted sulfonamide selective bcl-2 inhibitor
CN111848607B (zh) * 2020-07-22 2023-03-17 长沙创新药物工业技术研究院有限公司 一种新型bcl-2/bcl-xl抑制剂、药物组合物及用途
CN114073703B (zh) * 2020-08-21 2022-12-30 苏州亚盛药业有限公司 用于治疗非酒精性脂肪肝炎的组合物和方法
WO2022089463A1 (zh) * 2020-10-28 2022-05-05 杭州和正医药有限公司 Bcl-2蛋白凋亡诱导剂及应用
CN114736203A (zh) * 2021-01-07 2022-07-12 南京天印健华医药科技有限公司 作为bcl-2抑制剂的杂环化合物
WO2022198069A1 (en) * 2021-03-19 2022-09-22 Eil Therapeutics, Inc. Compounds having ((3-nitrophenyl)sulfonyl)acetamide as bcl-2 inhibitors
CN117616023A (zh) * 2021-04-13 2024-02-27 爱新医药科技(香港)有限公司 Bcl-2或bcl-2/bcl-xl调节剂及其用途
WO2022253313A1 (zh) 2021-06-04 2022-12-08 正大天晴药业集团股份有限公司 三氟甲基取代的磺酰胺类化合物的磷酸酯
WO2023030363A1 (en) * 2021-08-31 2023-03-09 Beigene, Ltd. Solid forms of bcl-2 inhibitors, method of preparation, and use thereof
IT202100025976A1 (it) 2021-10-06 2023-04-06 Univ Degli Studi Di Perugia Combinazione di principi attivi per il trattamento della leucemia acuta mieloide (LAM) con mutazione della nucleofosmina (NPM1)
WO2023107606A1 (en) 2021-12-09 2023-06-15 University Of Florida Research Foundation, Incorporated Bcl-xl/bcl-2 dual degraders for treatment of cancers
WO2024012557A1 (en) * 2022-07-15 2024-01-18 Berrybio (Hong Kong) Limited Anti-apoptotic bcl-2 family protein degraders, pharmaceutical compositions, and therapeutic applications
WO2024017354A1 (en) * 2022-07-21 2024-01-25 Beigene, Ltd. Methods of treating multiple myeloma using bcl-2 inhibitor
CN115260191B (zh) * 2022-09-29 2022-12-27 上海睿跃生物科技有限公司 哌啶类化合物及其制备方法和应用
KR102598137B1 (ko) 2022-11-24 2023-11-06 율촌화학 주식회사 고차단성 생분해 필름 및 이의 제조방법

Family Cites Families (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2579596B1 (fr) * 1985-03-26 1987-11-20 Inst Nat Sante Rech Med (imidazolyl-4) piperidines, leur preparation et leur application en therapeutique
CA1338238C (en) * 1988-01-07 1996-04-09 David John Carini Angiotensin ii receptor blocking imidazoles and combinations thereof with diuretics and nsaids
EP0400835A1 (en) * 1989-05-15 1990-12-05 Merck & Co. Inc. Substituted benzimidazoles as angiotensin II antagonists
GB9110625D0 (en) * 1991-05-16 1991-07-03 Glaxo Group Ltd Chemical compounds
PT672031E (pt) * 1992-12-02 2003-06-30 Pfizer Dieteres de catecol como inibidores selectivos de pde iv
MY115155A (en) 1993-09-09 2003-04-30 Upjohn Co Substituted oxazine and thiazine oxazolidinone antimicrobials.
ES2214546T3 (es) 1995-09-15 2004-09-16 PHARMACIA & UPJOHN COMPANY N-oxidos de aminoariloxazolidinona.
EP1019399A1 (en) * 1997-10-03 2000-07-19 Merck Frosst Canada & Co. Aryl thiophene derivatives as pde iv inhibitors
US20030220234A1 (en) 1998-11-02 2003-11-27 Selvaraj Naicker Deuterated cyclosporine analogs and their use as immunodulating agents
AU767456B2 (en) 1998-07-06 2003-11-13 Bristol-Myers Squibb Company Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists
DE19830430A1 (de) * 1998-07-08 2000-01-13 Hoechst Marion Roussel De Gmbh Schwefelsubstituierte Sulfonylamino-carbonsäure-N-arylamide, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
GB9918037D0 (en) 1999-07-30 1999-09-29 Biochemie Gmbh Organic compounds
CA2395772C (en) 1999-12-28 2010-09-28 Eisai Co., Ltd. Sulfonamide-containing heterocyclic compounds
GB2361003A (en) * 2000-04-07 2001-10-10 Astrazeneca Ab Novel compounds
US20020055631A1 (en) 2000-09-20 2002-05-09 Augeri David J. N-acylsulfonamide apoptosis promoters
US6720338B2 (en) 2000-09-20 2004-04-13 Abbott Laboratories N-acylsulfonamide apoptosis promoters
UY26942A1 (es) * 2000-09-20 2002-04-26 Abbott Lab N-acilsulfonamidas promotoras de la apoptosis
US6995162B2 (en) 2001-01-12 2006-02-07 Amgen Inc. Substituted alkylamine derivatives and methods of use
AU2002259204B2 (en) 2001-06-06 2008-01-17 Eli Lilly And Company Benzoylsulfonamides and sulfonylbenzamidines for use as antitumour agents
US20030059489A1 (en) 2001-09-24 2003-03-27 Canolio Inc. Genital lubricating compositions and uses thereof
WO2003026587A2 (en) * 2001-09-26 2003-04-03 Bristol-Myers Squibb Company Compounds useful for treating hepatitus c virus
FR2836914B1 (fr) * 2002-03-11 2008-03-14 Aventis Pharma Sa Indazoles substitues, compositions les contenant, procede de fabrication et utilisation
GB0215650D0 (en) * 2002-07-05 2002-08-14 Cyclacel Ltd Bisarylsufonamide compounds
US6995787B2 (en) 2002-08-21 2006-02-07 Adams Steven L Sports projectile and camera apparatus
WO2005024636A1 (ja) 2003-09-04 2005-03-17 Hitachi Ulsi Systems Co., Ltd. 半導体装置
US7642260B2 (en) 2003-11-13 2010-01-05 Abbott Laboratories, Inc. Apoptosis promoters
US8614318B2 (en) * 2003-11-13 2013-12-24 Abbvie Inc. Apoptosis promoters
WO2005049593A2 (en) * 2003-11-13 2005-06-02 Abbott Laboratories N-acylsulfonamide apoptosis promoters
US7973161B2 (en) * 2003-11-13 2011-07-05 Abbott Laboratories Apoptosis promoters
US7767684B2 (en) 2003-11-13 2010-08-03 Abbott Laboratories Apoptosis promoters
EP1737850B1 (en) 2004-04-19 2007-10-03 Symed Labs Limited A novel process for the preparation of linezolid and related compounds
JP5064213B2 (ja) * 2004-06-17 2012-10-31 インフィニティ・ディスカバリー・インコーポレイテッド Ｂｃｌタンパク質と結合パートナーとの相互作用を阻害する化合物および方法
US7429661B2 (en) 2004-07-20 2008-09-30 Symed Labs Limited Intermediates for linezolid and related compounds
US7361764B2 (en) * 2004-07-27 2008-04-22 Sgx Pharmaceuticals, Inc. Pyrrolo-pyridine kinase modulators
US7511013B2 (en) 2004-09-29 2009-03-31 Amr Technology, Inc. Cyclosporin analogues and their pharmaceutical uses
EP2757099B1 (en) * 2005-05-12 2017-08-23 AbbVie Bahamas Limited Apoptosis promoters
US8624027B2 (en) 2005-05-12 2014-01-07 Abbvie Inc. Combination therapy for treating cancer and diagnostic assays for use therein
MX2007014327A (es) 2005-05-16 2008-02-11 Irm Llc Derivados de pirrolopiridina como inhibidores de cinasa de proteina.
TW200716636A (en) 2005-05-31 2007-05-01 Speedel Experimenta Ag Heterocyclic spiro-compounds
EP3088400A1 (en) 2005-06-22 2016-11-02 Plexxikon Inc. Pyrrolo[2,3-b]pyridine derivatives as protein kinase inhibitors
US7514068B2 (en) 2005-09-14 2009-04-07 Concert Pharmaceuticals Inc. Biphenyl-pyrazolecarboxamide compounds
US20070115787A1 (en) * 2005-11-23 2007-05-24 Seagate Technology Llc Planar optical device for generating optical nanojets
CN101534904B (zh) * 2006-09-05 2013-11-06 Abbvie公司 治疗血小板过量的bcl抑制剂
US8796267B2 (en) 2006-10-23 2014-08-05 Concert Pharmaceuticals, Inc. Oxazolidinone derivatives and methods of use
US20080182845A1 (en) 2006-11-16 2008-07-31 Abbott Laboratories Method of preventing or treating organ, hematopoietic stem cell or bone marrow transplant rejection
WO2008098857A1 (en) 2007-02-15 2008-08-21 F. Hoffmann-La Roche Ag 2-aminooxazolines as taar1 ligands
US8536157B2 (en) 2007-04-13 2013-09-17 The University Of Melbourne Non-steroidal compounds
KR20100012031A (ko) 2007-04-19 2010-02-04 콘서트 파마슈티컬즈, 인크. 중수소화된 모르폴리닐 화합물
US7531685B2 (en) 2007-06-01 2009-05-12 Protia, Llc Deuterium-enriched oxybutynin
WO2009035598A1 (en) 2007-09-10 2009-03-19 Concert Pharmaceuticals, Inc. Deuterated pirfenidone
US20090118238A1 (en) 2007-09-17 2009-05-07 Protia, Llc Deuterium-enriched alendronate
US20090082471A1 (en) 2007-09-26 2009-03-26 Protia, Llc Deuterium-enriched fingolimod
US20090088416A1 (en) 2007-09-26 2009-04-02 Protia, Llc Deuterium-enriched lapaquistat
JP2010540635A (ja) 2007-10-02 2010-12-24 コンサート ファーマシューティカルズ インコーポレイテッド ピリミジンジオン誘導体
US20090098118A1 (en) * 2007-10-15 2009-04-16 Thomas Friess Combination therapy of a type ii anti-cd20 antibody with an anti-bcl-2 active agent
US20090105338A1 (en) 2007-10-18 2009-04-23 Protia, Llc Deuterium-enriched gabexate mesylate
WO2009051782A1 (en) 2007-10-18 2009-04-23 Concert Pharmaceuticals Inc. Deuterated etravirine
CA2703591C (en) 2007-10-26 2013-05-07 Concert Pharmaceuticals, Inc. Deuterated darunavir
US8168784B2 (en) * 2008-06-20 2012-05-01 Abbott Laboratories Processes to make apoptosis promoters
US20100160322A1 (en) 2008-12-04 2010-06-24 Abbott Laboratories Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
US8557983B2 (en) 2008-12-04 2013-10-15 Abbvie Inc. Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
UA108193C2 (uk) * 2008-12-04 2015-04-10 Апоптозіндукуючий засіб для лікування раку і імунних і аутоімунних захворювань
SG10201500767RA (en) 2008-12-05 2015-04-29 Abbvie Inc Sulfonamide derivatives as bcl-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases
US8563735B2 (en) 2008-12-05 2013-10-22 Abbvie Inc. Bcl-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases
US8586754B2 (en) 2008-12-05 2013-11-19 Abbvie Inc. BCL-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases
WO2010077740A2 (en) 2008-12-09 2010-07-08 Cytokine Pharmasciences, Inc. Novel antiviral compounds, compositions, and methods of use
US20120094963A1 (en) 2008-12-23 2012-04-19 of Queen Elizabeth near Dublin Targeting prodrugs and compositions for the treatment of gastrointestinal diseases
ES2593427T3 (es) 2009-01-19 2016-12-09 Abbvie Inc. Agentes inductores de la apoptosis para el tratamiento del cáncer y de enfermedades inmunes y autoinmunes
SG193849A1 (en) 2009-01-19 2013-10-30 Abbott Lab Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
US8546399B2 (en) 2009-05-26 2013-10-01 Abbvie Inc. Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases
KR20170037683A (ko) 2009-05-26 2017-04-04 애브비 아일랜드 언리미티드 컴퍼니 암，면역 질환 및 자가면역 질환의 치료를 위한 아폽토시스-유도제

Also Published As

Publication number Publication date
CA3052016A1 (en) 2010-12-02
HK1163099A1 (en) 2012-09-07
CN104906100A (zh) 2015-09-16
KR20230128571A (ko) 2023-09-05
CA2759182C (en) 2016-06-07
SG10201704742YA (en) 2017-07-28
CA2759182A1 (en) 2010-12-02
CR20170019A (es) 2017-05-12
NO2017023I1 (no) 2017-05-29
EP3656771A1 (en) 2020-05-27
UY37825A (es) 2020-02-28
CN109966294A (zh) 2019-07-05
RS54234B2 (sr) 2024-02-29
MX2011012257A (es) 2011-12-16
CN104876927B (zh) 2017-06-23
EP2435432B3 (en) 2023-10-25
CN102448959A (zh) 2012-05-09
TW201506025A (zh) 2015-02-16
JP2015110605A (ja) 2015-06-18
NL300873I2 (nl) 2017-10-24
EP2435432B1 (en) 2015-06-24
IL215644A (en) 2017-08-31
NZ595708A (en) 2014-03-28
RU2011152973A (ru) 2013-07-10
CA3206963A1 (en) 2010-12-02
CL2011002949A1 (es) 2012-05-25
IL253891A0 (en) 2017-10-31
US20110124628A1 (en) 2011-05-26
LTPA2017015I1 (lt) 2017-06-12
AU2010254160A1 (en) 2011-11-24
UY32668A (es) 2010-12-31
CY2017019I2 (el) 2018-01-10
SMT201500225B (it) 2015-10-30
DK2435432T3 (en) 2015-08-31
IL286036A (en) 2021-10-31
JP2012528178A (ja) 2012-11-12
KR101723378B1 (ko) 2017-04-06
EP2944638A1 (en) 2015-11-18
IL299019A (en) 2023-02-01
CN104876927A (zh) 2015-09-02
KR20190086591A (ko) 2019-07-22
LTC2435432I2 (lt) 2018-06-11
BRPI1014359A2 (pt) 2016-04-05
TWI561523B (en) 2016-12-11
BRPI1014359B1 (pt) 2019-11-05
KR20180124164A (ko) 2018-11-20
WO2010138588A3 (en) 2011-04-07
SI2435432T1 (sl) 2015-10-30
RU2628885C2 (ru) 2017-08-22
IL269092A (en) 2019-11-28
HRP20151001T4 (hr) 2024-02-16
KR101920202B1 (ko) 2018-11-21
JP2017048219A (ja) 2017-03-09
UA106079C2 (uk) 2014-07-25
PL2435432T3 (pl) 2015-12-31
KR102001418B1 (ko) 2019-07-19
BR122019016429B1 (pt) 2020-03-24
CN102448959B (zh) 2015-06-17
HRP20151001T1 (hr) 2015-10-23
ES2546294T3 (es) 2015-09-22
AU2010254160C1 (en) 2023-07-06
RU2015154494A (ru) 2017-06-22
WO2010138588A2 (en) 2010-12-02
PT2435432E (pt) 2015-10-13
DOP2011000367A (es) 2017-07-31
CY1117423T1 (el) 2017-04-26
JP2022033939A (ja) 2022-03-02
IL215644A0 (en) 2012-01-31
KR20150065947A (ko) 2015-06-15
FI2435432T6 (fi) 2023-11-21
KR20180049164A (ko) 2018-05-10
JP6353506B2 (ja) 2018-07-04
SG175253A1 (en) 2011-11-28
PL2435432T6 (pl) 2024-02-12
KR101659583B1 (ko) 2016-09-29
JP2020023545A (ja) 2020-02-13
RU2535347C2 (ru) 2014-12-10
RU2014132884A (ru) 2015-12-27
KR20120034671A (ko) 2012-04-12
UY33047A (es) 2011-09-30
EP2435432A2 (en) 2012-04-04
CN109897038B (zh) 2022-04-05
AU2010254160B2 (en) 2015-02-12
CY2017019I1 (el) 2018-01-10
AR109974A2 (es) 2019-02-13
WO2010138588A9 (en) 2011-05-05
US8580794B2 (en) 2013-11-12
MX339469B (es) 2016-05-27
JP2023040165A (ja) 2023-03-22
CR20110632A (es) 2012-02-15
PH12015500297A1 (en) 2015-12-07
ZA201108616B (en) 2015-12-23
MY155645A (en) 2015-11-13
MX2019012154A (es) 2019-11-21
DK2435432T6 (da) 2023-12-18
ECSP11011554A (es) 2012-01-31
HK1215576A1 (zh) 2016-09-02
RU2535347C3 (ru) 2019-05-14
PE20120345A1 (es) 2012-05-17
TWI476195B (zh) 2015-03-11
NO2017023I2 (no) 2017-05-29
KR20170037683A (ko) 2017-04-04
CA2929347A1 (en) 2010-12-02
JP5747025B2 (ja) 2015-07-08
JP6038195B2 (ja) 2016-12-07
CN109897038A (zh) 2019-06-18
HUE027698T2 (en) 2016-10-28
KR20190130676A (ko) 2019-11-22
TWI537269B (zh) 2016-06-11
TW201607946A (zh) 2016-03-01
JP2018138577A (ja) 2018-09-06
TW201107323A (en) 2011-03-01
RU2573832C2 (ru) 2016-01-27
RS54234B1 (en) 2015-12-31
ME02205B (me) 2016-02-20
HUS1700021I1 (hu) 2017-06-28
CO6480950A2 (es) 2012-07-16

Similar Documents

Publication Publication Date Title
AR076705A1 (es) Agentes inductores de la apoptosis para el tratamiento del cancer y enfermedades inmunes y autoinmunes
AR079124A1 (es) Agentes inductores de apoptosis para el tratamiento del cancer y de enfermedades inmunes y autoinmunes
AR076946A1 (es) Agentes inductores de apoptosis para el tratamiento de cancer y enfermedades inmunes y autoinmunes
AR081552A1 (es) Agentes inductores de apoptosis para el tratamiento del cancer y de enfermedades inmunes y autoinmunes
AR076945A1 (es) Agentes inductores de apoptosis con selectividad por bcl-2 para el tratamiento de cancer y enfermedades inmunes
AR074510A1 (es) Agentes inductores de apoptosis con selectividad por bcl-2 para el tratamiento de cancer y enfermedades inmunes
AR124117A2 (es) Agentes inductores de la apoptosis que pueden usarse para tratar el cáncer y las enfermedades inmunes y autoinmunes
AR089527A1 (es) Inhibidores de bromodominios
AR083855A1 (es) Inhibidores de nampt y rock
AR091023A1 (es) Inhibidores del nampt
AR098912A1 (es) Inhibidores de syk
AR101177A1 (es) Inhibidores de la syk
AR105911A1 (es) Inhibidores de hdac8 bicíclicos fusionados [6,6]
AR108207A1 (es) Derivados de pirrolo[2,3-c]piridina, inhibidores de bromodominios
AR104720A1 (es) Moduladores de ccr2
AR103252A1 (es) Compuestos de quinazolina
AR065499A1 (es) Inhibidores de serino proteasas.composiciones farmaceuticas
RU2016134677A (ru) Композиции изоиндолина и способы лечения нейродегенеративного заболевания
AR101528A1 (es) Inhibidores de cdk9 quinasa de pirrolo[2,3-b]piridina
AR088328A1 (es) Agentes inductores de la apoptosis que pueden usarse para tratar el cancer y las enfermedades inmunes y autoinmunes
AR089489A1 (es) Derivados de tieno[3,2-d]pirimidina que tienen actividad inhibidora por las quinasas de las proteinas
AR085607A1 (es) Inhibidores de la mst1 quinasa y metodos para su utilizacion
AR100006A1 (es) Derivados de tubulisina
AR116115A1 (es) Dimetil amino azetidina amidas como inhibidores de jak
AR071833A1 (es) Inhibidores de quinasas (limk2), composiciones que los comprenden y metodos para tratar o prevenir enfermedades

Legal Events

Date Code Title Description
FG Grant, registration